In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HeartFlow: Disrupting The Diagnostic Paradigm In Cardiology

Executive Summary

Most current cardiac diagnostic imaging tests are highly inexact, relying heavily on clinicians' observations. HeartFlow is adapting advanced computer modeling to cardiology to produce a precise, predictive, noninvasive diagnostic that doubles as a treatment planning tool. The test could eliminate unnecessary procedures for patients and save the system money, but is that what interventionalists want?
Advertisement

Related Content

HeartFlow Expects FDA Go-Ahead For Imaging-Based FFR Software Any Day Now
Start-Up News
The Fogarty Institute For Innovation: A Device Incubator For Difficult Times
HeartFlow: Disrupting The Diagnostic Paradigm In Cardiology
HeartPort's Quiet Exit
HeartPort's Quiet Exit
HeartPort: Still Beating
HeartPort: Still Beating
Re-Starting Heartport
Be Still My Beating Heart: Can Heartport Deliver?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel